News
2024
- 20 September 2024
Groundbreaking research into pharmaceuticals in Salzburg
Bioscientist Nicole Meisner-Kober is conducting research at the Ludwig Boltzmann Institute in Salzburg into the development of completely new active substances for the treatment of a wide range of diseases, especially cancer. She and her team are investigating how so-called vesicles could be used as transporters for active substances in the body. The institute is funded with 15 million euros by the Ludwig Boltzmann Society and the state of Salzburg.
This basic research, which is carried out at the Paris Lodron University of Salzburg, could lead to new therapies and treatment methods that do not yet exist. At the same time, the Ludwig Boltzmann Institute is a prime example of Salzburg’s expertise in the field of life sciences, i.e. research and development in health and medicine. Another special feature of the institute is that it bridges the gap between basic research and large-scale application.
Further details about the investment and its significance for Salzburg’s life sciences sector are also provided by Salzburger Landeskorresponde
- Die Presse: Ein trojanisches Pferd für neue MedikamenteEin trojanisches Pferd für neue Medikamente | DiePresse.com
Mit Fokus auf Gesundheit: Drei neue Boltzmann-Institute präsentiert | SN.at
PLUS: Ludwig Boltzmann Institut (LBI) für Health Science – Paris Lodron Universität Salzburg
2023
- Innovation Salzburg: von Mozart bis Hightech
Von Mozart bis Hightech – Innovation Salzburg (innovation-salzburg.at)
- The program ‘Österreich Bild – Von Mozart bis Hightech’ from June 11th, 2023 reports on the Salzburg location with a contribution by Prof. Nicole Meisner-Kober and the work of her team (from about minute 02:35)
- EV Club by International Society for Extracellular Vesicles (15 Feb 2023): In this EVClub, Melanie Schürz & Nicole Meisner-Kober present “High content imaging for rigorous characterisation of single extracellular vesicles using standard laboratory equipment and a new open-source ImageJ/Fiji plugin”, described elsewhere as a “democratization” of single-EV imaging! Hosted and moderated by Ken Witwer
2022
- Salzburger Nachrichten
Forscherin möchte Krebs heilen
2020
-
FFG Talente Praktika für Schülerinnen und Schüler 2020
AG Meisner-Kober was awarded for its outstanding internship support.
In summer 2020, the FFG Talent Internships took place throughout Austria. This gives pupils the opportunity to gain practical experience in research in order to get an insight into later career fields in the STEM sector. The internships are competitively advertised and financed by the FFG. Two student internships were awarded in the research group of Nicole Meisner-Kober (PLUS, Department of Biosciences, Chemical Biology and Biological Therapeutics), where the students had the opportunity to work in the EV-TT Transfer Centre on a project on EV-based delivery of antiviral agents against Covid-19. The interns then had the opportunity to report on their internship in a report. Hanna Aberger’s report was awarded a prize among the 20 best internship reports in Austria. The members of the Meisner-Kober working group – Univ. Prof. Dr Nicole Meisner-Kober, Dr Eva Klinglmayr, Dr Melanie Schürz and Heloisa Melo Benirschke, BSc – were also awarded for their outstanding internship support on the topic of “Engineering of EVs”. Due to the current Covid-19 measures, the award ceremony did not take place in the Vienna Urania as planned, but online. [ continue to article]
- Salzburger Nachrichten
Körpereigenen Paketdienst für Therapien nutzen
- Weiterer Erfolg für Salzburg als Forschungsstandort: Boehringer Ingelheim kooperiert mit Universität Salzburg bei Vesikelforschung
https://service.salzburg.gv.at/lkorrj/detail?nachrid=64144
- EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
